Chia Tai Enterprises International Limited (HK:3839)
:3839
Want to see HK:3839 full AI Analyst Report?
Top Page
Chia Tai Enterprises International
(3839)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$9.50
â–²(39.91% Upside)
Action:Upgraded
Date:05/05/26
The score is driven primarily by improved financial performance in 2025 (growth, margins, and low leverage) and a favorable low P/E valuation. These positives are tempered by overextended technical momentum signals (very high RSI/Stoch) and a history of uneven cash flow, which adds execution and pullback risk.
Positive Factors
Conservative, improving leverage
Debt-to-equity falling to ~0.17 in 2025 with equity growth materially improves financial resilience. Lower leverage increases flexibility for capex, working-capital cycles and adverse shocks, reducing refinancing risk and supporting durable operations and strategic choices over the next 2–6 months.
Negative Factors
Volatile profitability and margin erosion
Significant margin compression from historical gross margins (~24–27% earlier to ~14% in 2025) and prior negative net income highlight structural pressure on pricing or costs. Persistent margin erosion would limit sustainable profitability and ROE, constraining resilience beyond short-term rebounds.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative, improving leverage
Debt-to-equity falling to ~0.17 in 2025 with equity growth materially improves financial resilience. Lower leverage increases flexibility for capex, working-capital cycles and adverse shocks, reducing refinancing risk and supporting durable operations and strategic choices over the next 2–6 months.
Read all positive factors
Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.14B
Dividend YieldN/A
Average Volume (3M)166.49K
Price to Earnings (P/E)9.6
Beta (1Y)1.47
Revenue Growth12.63%
EPS Growth68.37%
CountryHK
Employees900
SectorHealthcare
Sector Strength45
IndustryAgricultural Farm Products
Share Statistics
EPS (TTM)0.11
Shares Outstanding240,718,300
10 Day Avg. Volume121,886
30 Day Avg. Volume166,494
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.85
Price to Sales (P/S)0.44
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chia Tai Enterprises International Business Overview & Revenue Model
Company Description
Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, ...
How the Company Makes Money
null...
Chia Tai Enterprises International Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.10M | 536.71M | 307.75M | 173.98M | 159.24M | 142.41M |
| Gross Profit | 72.73M | 77.55M | 48.93M | 30.18M | 39.19M | 34.76M |
| EBITDA | 39.46M | 48.28M | 17.51M | 11.29M | 5.17M | 12.38M |
| Net Income | 26.25M | 32.10M | 11.17M | 2.55M | -6.68M | 19.56M |
Balance Sheet | ||||||
| Total Assets | 448.53M | 461.60M | 422.21M | 377.37M | 350.58M | 365.22M |
| Cash, Cash Equivalents and Short-Term Investments | 35.49M | 39.83M | 32.38M | 37.61M | 30.86M | 31.09M |
| Total Debt | 59.09M | 47.55M | 69.17M | 78.17M | 49.10M | 42.61M |
| Total Liabilities | 163.63M | 153.76M | 161.70M | 125.36M | 94.83M | 81.69M |
| Stockholders Equity | 255.65M | 277.11M | 234.77M | 228.43M | 230.85M | 253.06M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 28.04M | -2.56M | -27.17M | -10.38M | -28.46M |
| Operating Cash Flow | 0.00 | 34.33M | 11.29M | -16.06M | 5.63M | -10.91M |
| Investing Cash Flow | 0.00 | -2.79M | -9.27M | -7.14M | -15.64M | -9.84M |
| Financing Cash Flow | 0.00 | -24.38M | -7.07M | 30.23M | 10.38M | 19.36M |
Chia Tai Enterprises International Technical Analysis
Positive
6.79
Price Trends
7.41
Positive
6.99
Positive
7.17
Positive
Market Momentum
0.29
Positive
57.53
Neutral
34.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Positive. The current price of 6.79 is below the 20-day moving average (MA) of 8.48, below the 50-day MA of 7.41, and below the 200-day MA of 7.17, indicating a neutral trend. The MACD of 0.29 indicates Positive momentum. The RSI at 57.53 is Neutral, neither overbought nor oversold. The STOCH value of 34.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3839.
Chia Tai Enterprises International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$2.14B | 9.62 | 12.24% | ― | 12.63% | 68.37% | |
61 Neutral | HK$17.68B | 26.53 | 12.65% | 5.11% | -4.09% | -22.73% | |
60 Neutral | HK$641.83M | 18.09 | 5.66% | 2.92% | 2.57% | -1.27% | |
57 Neutral | HK$19.49B | 22.15 | 7.26% | 3.13% | 5.48% | -49.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.06B | -10.09 | -1.66% | 3.66% | -10.68% | -737.07% | |
46 Neutral | HK$351.03M | 43.65 | -1.17% | 7.50% | 59.60% | -351.02% |
* Healthcare Sector Average
HK:3839
Chia Tai Enterprises International
8.44
6.58
353.76%
HK:3933
The United Laboratories International Holdings
8.96
-3.65
-28.95%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.60
-0.50
-23.66%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.03
-10.00%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.09
-0.29
-21.01%
HK:0512
Grand Pharmaceutical Group Limited
5.49
-3.31
-37.61%
Chia Tai Enterprises International Corporate Events
Chia Tai Enterprises Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Apr 29, 2026
Chia Tai Enterprises International has called its annual general meeting for 9 June 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements and reports for the year ended 31 December 2025, and vote...
Chia Tai Enterprises Sets May Board Meeting to Approve Q1 2026 Results
Apr 27, 2026
Chia Tai Enterprises International Limited has scheduled a board meeting for 12 May 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. The meeting date signals the upcoming release of the compan...
Chia Tai Enterprises Flags Lower Q1 2026 Profit on Weaker Chlortetracycline Earnings
Apr 22, 2026
Chia Tai Enterprises International said it expects to post a consolidated profit attributable to shareholders of about US$5.5 million for the three months ended 31 March 2026, down from US$7.7 million a year earlier. The decline is mainly attribut...
Chia Tai Enterprises to Build New RMB28.9 Million Fermentation Facility in Henan
Mar 16, 2026
Chia Tai Enterprises International, via its 69.7%-owned subsidiary Zhumadian Huazhong CT, is investing in a new fermentation facility in Zhumadian City, Henan Province, to expand its fermentation and extraction capabilities. The project underscore...
Chia Tai Enterprises Plans Biotech-Focused Rebrand as CPBIO Holding
Mar 16, 2026
Chia Tai Enterprises International plans to change its English name to CPBIO Holding Company Limited and adopt a new Chinese name, subject to shareholder approval at the annual general meeting and clearance from Bermuda’s Registrar of Compan...
Chia Tai Enterprises Overhauls Top Management as Chairman Assumes Executive Role
Feb 24, 2026
Chia Tai Enterprises International has reshaped its leadership structure, with chairman Soopakij Chearavanont shifting from non-executive to executive director to take on a more hands-on role, while veteran executive Chawalit Na Muangtoun becomes ...
Chia Tai Enterprises Clarifies Board and Committee Roles to Bolster Governance
Feb 24, 2026
Chia Tai Enterprises International Limited has released an updated list of its directors and detailed their roles across key board committees, underscoring its governance framework. The announcement confirms the composition of the audit, remunerat...
Chia Tai Enterprises International Triples 2025 Profit on Strong Revenue Growth
Feb 24, 2026
Chia Tai Enterprises International posted a sharp improvement in results for 2025, with revenue jumping to US$535.9 million from US$307.7 million and gross profit rising to US$77.4 million. The group’s profit attributable to shareholders nea...
Chia Tai Enterprises Sets Board Meeting to Approve 2025 Results and Consider Final Dividend
Feb 6, 2026
Chia Tai Enterprises International Limited has scheduled a board meeting for 24 February 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. At the same meeting, the boar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.